IndiaNifty 5024,334.55▲ +0.48%
IndiaBSE Sensex77,656.09▲ +0.37%
IndiaNifty Bank57,514.20▼ -0.02%
IndiaNifty IT30,771.80▲ +0.57%
IndiaNifty Auto29,216.90▲ 0.00%
IndiaNifty Pharma26,564.00▲ +0.85%
IndiaNifty FMCG47,706.95▲ 0.00%
USS&P 5007,677.28▲ +0.32%
USDow Jones53,577.40▲ +0.30%
USNASDAQ26,151.30▲ +0.66%
UKFTSE 10010,886.20▲ +0.29%
JapanNikkei 22565,960.30▲ +0.16%
Hong KongHang Seng25,729.45▲ +0.86%
GermanyDAX26,266.14▲ +0.61%
FranceCAC 408,439.20▼ -0.16%
AustraliaASX 2009,175.30▲ +0.12%
IndiaNifty 5024,334.55▲ +0.48%
IndiaBSE Sensex77,656.09▲ +0.37%
IndiaNifty Bank57,514.20▼ -0.02%
IndiaNifty IT30,771.80▲ +0.57%
IndiaNifty Auto29,216.90▲ 0.00%
IndiaNifty Pharma26,564.00▲ +0.85%
IndiaNifty FMCG47,706.95▲ 0.00%
USS&P 5007,677.28▲ +0.32%
USDow Jones53,577.40▲ +0.30%
USNASDAQ26,151.30▲ +0.66%
UKFTSE 10010,886.20▲ +0.29%
JapanNikkei 22565,960.30▲ +0.16%
Hong KongHang Seng25,729.45▲ +0.86%
GermanyDAX26,266.14▲ +0.61%
FranceCAC 408,439.20▼ -0.16%
AustraliaASX 2009,175.30▲ +0.12%
Invest and Educate
NYQ · USD

Johnson & Johnson

JNJ
273.14
▲ 0.10 (+0.04%)
Price Chart
6MO · Daily
2026-03-102026-04-072026-05-042026-06-012026-06-292026-07-272026-08-25221.32236.32251.32266.32273.41
Key Ratios & Fundamentals
Market Cap
630.74B
P/E (TTM)
30.36
Fwd P/E
21.27
P/B
7.42
P/S
6.44
Book Value
35.28
EPS (TTM)
8.62
Fwd EPS
12.31
Div Yield
+2.06%
Beta
0.23
ROE
+25.74%
ROA
+8.60%
D/E
57.71
Current Ratio
1.09
Profit Margin
+21.48%
Op Margin
+29.19%
52W High
274.90
52W Low
173.33
50D Avg
251.31
200D Avg
229.78
Avg Volume
8.09M
Shares Out
2.41B
Sector
Healthcare
Industry
Drug Manufacturers - General
About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

SWOT Analysis
Auto-derived from fundamentals
Strengths
  • Exceptional ROE of 25.7% — highly efficient use of shareholder capital
  • Robust net profit margin of 21.5% — strong pricing power
  • Superior operating margin of 29.2% — strong operational leverage
  • Reasonable dividend yield of 2.06%
  • Low beta of 0.23 — defensive characteristics
Weaknesses
  • No major red flags in reported financials — continue monitoring quarterly results
Opportunities
  • Forward P/E of 21.3x is below trailing — market expects earnings growth
  • Positioned in Healthcare — defensive sector, aligned with respective macro cycles
Threats
  • High PEG of 4.56 — growth may already be priced in
  • Trading near 52-week high (87% of range) — limited upside before pullback
Latest News · Johnson & Johnson
10 stories
How Large Does Your Portfolio Need to Be to Generate $16,500 a Month?
The yield you chase to replace a six-figure income determines not just how much capital you need, but whether that income holds up a decade from now or quietly erodes beneath you.
24/7 Wall St.·2h ago
Eli Lilly Found a New Gear. You Paid For It.
Beyond strong drugs, the stock’s ascent was powered by its notable profitability.
Trefis·8h ago
J&J's First-In-Disease Approval Barely Moves a $666 Billion Stock
Imaavy validates another use for J&J's antibody platform, although the initial patient population remains small.
GuruFocus.com·9h ago
J&J’s Imaavy secures expanded US approval in rare blood disorder
The FDA approval marks another successful step in J&J’s aim of achieving $5bn in peak sales for the drug.
Pharmaceutical Technology·9h ago
J&J's Imaavy Gets FDA Approval as the First Treatment for wAIHA
JNJ's Imaavy wins FDA approval for wAIHA, becoming the first treatment specifically indicated for the rare autoimmune disease.
Zacks·10h ago
The Floor Under BSX Stock Is Being Tested Again
Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth.
Trefis·10h ago
Johnson & Johnson Is Near a Record High. Is There Still Room to Run?
Johnson and Johnson has surged over 54% in a year, cleared a major FDA hurdle, and raised its guidance, yet something about the current setup gives pause before hitting buy.
24/7 Wall St.·10h ago
LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.
Zacks·11h ago
The Hospital Bet That Reframes The Intuitive Surgical Stock Story
While investors fixate on a slowdown in current procedures, hospitals are accelerating their investment in the company's core platform, revealing a crucial, under-appreciated strength.
Trefis·11h ago
“Give Me Anything But Tech”: Jim Cramer’s Bold Call on the Market’s Next Big Rotation
Jim Cramer declared the data center trade dead on live television and named the stocks he wants instead, but the rotation he described carries a flaw that Wall Street is quietly ignoring.
24/7 Wall St.·13h ago
Invest & Educate · Data: Yahoo Finance · News: ET · Mint · Moneycontrol
PrivacyTermsEducational use only. Not investment advice.